Company release, 29 March 2024 at 9:00 a.m. (EET)

Nightingale Health Plc (“Nightingale Health”) announced on 7 March 2024, that it has agreed on an acquisition where it purchases all shares of the Japanese company Welltus Inc. The transaction was subject to certain conditions, which have been fulfilled and the transaction has been completed. Welltus Inc will be reported as part of Nightingale Health Group as of 29 March 2024.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com